Latest Funding News

Vulcan Steel is set to acquire Roofing Industries for NZ$88 million, marking a strategic entry into New Zealand’s steel roofing market. The deal is backed by an A$87 million equity raise, positioning Vulcan for growth in building materials.

Vulcan Steel Limited reported a 10.9% revenue decline in FY25 alongside a 24.1% drop in adjusted EBITDA, while announcing a fully underwritten NZ$96 million equity raise to fund the acquisition of Roofing Industries Limited. The deal marks Vulcan’s strategic entry into the New Zealand steel roofing and cladding market with expected earnings accretion and no change to its dividend policy.

Imricor Medical Systems reported a sharp 52% revenue decline and a 92% increase in net loss for H1 2025, offset by a $42.8 million equity raise boosting liquidity. The company is investing heavily in European sales and clinical trials while pursuing FDA approval.

Miramar Resources has partnered with Sumitomo Metal Mining Oceania in a multi-million-dollar joint venture to explore for large-scale nickel-copper-platinum group element deposits at the Bangemall Projects in Western Australia.

Cedar Woods Properties Limited delivered a robust FY25 with a 19% increase in net profit, underpinned by a diversified project portfolio and favourable market conditions. The company signals continued growth with a 10% NPAT guidance for FY26, supported by strong presales and strategic partnerships.

AUB Group Limited delivered a robust FY25 performance, with underlying NPAT rising 17.1% to AUD 200.2 million, driven by strategic acquisitions and margin improvements. The company’s aggressive UK retail expansion and diversified portfolio underpin a confident FY26 outlook.

Metals X Limited reported a robust half-year to June 2025 with profit after tax soaring 256% to $52.9 million, driven by higher tin sales and prices from its Renison joint venture. The company also progressed key projects and deepened strategic investments while reinforcing its ESG and safety frameworks.

Energy Transition Minerals Ltd has successfully raised $8 million through a heavily oversubscribed Share Purchase Plan, closing early due to strong shareholder demand. The funds will support the company’s critical minerals development strategy in Europe.

Activeport Group has successfully closed a fully underwritten rights issue, raising approximately $2.5 million to support its telecommunications software ambitions. The offer included free attaching options, signaling confidence in future growth.

Actinogen Medical reports steady progress in its Alzheimer’s and depression drug trials, backed by strong funding and strategic commercial planning. Key interim data from the pivotal XanaMIA trial is expected early next year.

Actinogen Medical reported a $14.7 million net loss for FY25 while progressing its lead drug Xanamem through pivotal Alzheimer’s and depression trials, with interim results expected in January 2026. The company has secured funding through mid-2026 and is preparing for commercialization.

Platinum Asia Investments has finalized its scheme of arrangement, transferring shares to an ETF structure and delisting from the ASX. Shareholders now hold units in the Platinum Asia Fund Complex ETF as the company undergoes a significant restructure.